Previously, Guerard has served as CEO of Othea, president and CEO of Graybug Vision and worldwide franchise head of ophthalmology at Novartis.
Guerard said: “QLS-111 represents a differentiated and potentially transformative approach to lowering intraocular pressure by targeting the episcleral vein through its novel vasodilatory mechanism.
“I look forward to working with Qlaris’ talented team to advance our phase 3 programme and prepare the organisation for commercialisation.”
Qlaris develops first-in-class therapies for unmet needs in ophthalmology, including its lead candidate QLS-111 which is designed to treat glaucoma.
Guerard has more than two decades of global leadership experience in ophthalmology.
